These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 20185312)

  • 61. Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity.
    Trimble N; Johnson AC; Foster A; Greenwood-van Meerveld B
    Neurogastroenterol Motil; 2007 Sep; 19(9):754-60. PubMed ID: 17539891
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Design and preparation of 2-benzamido-pyrimidines as inhibitors of IKK.
    Waelchli R; Bollbuck B; Bruns C; Buhl T; Eder J; Feifel R; Hersperger R; Janser P; Revesz L; Zerwes HG; Schlapbach A
    Bioorg Med Chem Lett; 2006 Jan; 16(1):108-12. PubMed ID: 16236504
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Synthesis and evaluation of 2-anilino-3-phenylsulfonyl-6-methylpyridines as corticotropin-releasing factor1 receptor ligands.
    Hartz RA; Arvanitis AG; Arnold C; Rescinito JP; Hung KL; Zhang G; Wong H; Langley DR; Gilligan PJ; Trainor GL
    Bioorg Med Chem Lett; 2006 Feb; 16(4):934-7. PubMed ID: 16297619
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Synthesis, in vitro biological investigation, and molecular dynamics simulations of thiazolopyrimidine based compounds as corticotrophin releasing factor receptor-1 antagonists.
    Elgiushy HR; Abou-Taleb NA; Holz GG; Chepurny OG; Pirmettis I; Kakabakos S; Karageorgos V; Liapakis G; Albohy A; Abouzid KAM; Hammad SF
    Bioorg Chem; 2021 Sep; 114():105079. PubMed ID: 34174633
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Optimising metabolic stability in lipophilic chemical space: the identification of a metabolically stable pyrazolopyrimidine CRF-1 receptor antagonist.
    Miller DC; Klute W; Calabrese A; Brown AD
    Bioorg Med Chem Lett; 2009 Nov; 19(21):6144-7. PubMed ID: 19782566
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Rapid microscale synthesis, a new method for lead optimization using robotics and solution phase chemistry: application to the synthesis and optimization of corticotropin-releasing factor1 receptor antagonists.
    Whitten JP; Xie YF; Erickson PE; Webb TR; De Souza EB; Grigoriadis DE; McCarthy JR
    J Med Chem; 1996 Oct; 39(22):4354-7. PubMed ID: 8893828
    [No Abstract]   [Full Text] [Related]  

  • 68. Synthesis and SAR of 2-aryloxy-4-alkoxy-pyridines as potent orally active corticotropin-releasing factor 1 receptor antagonists.
    Chen YL; Braselton J; Forman J; Gallaschun RJ; Mansbach R; Schmidt AW; Seeger TF; Sprouse JS; Tingley FD; Winston E; Schulz DW
    J Med Chem; 2008 Mar; 51(5):1377-84. PubMed ID: 18260619
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Discovery of a stable tripeptide targeting the N-domain of CRF1 receptor.
    Liapakis G; Karageorgos V; Andreadelis I; Holz GG; Dermitzaki E; Kordopati GG; Stylos EΚ; Spyridaki K; Poulaki S; Ntountaniotis D; Sakellaris S; Vanioti M; Kostagianni A; Marousis KD; Leonis G; Kokotos G; Venihaki M; Spyroulias GA; Tselios T; Margioris A; Tzakos AG; Mavromoustakos T
    Amino Acids; 2020 Sep; 52(9):1337-1351. PubMed ID: 32996057
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Chemical modification of aryl-1,2,3,6-tetrahydropyridinopyrimidine derivative to discover corticotropin-releasing factor(1) receptor antagonists: aryl-1,2,3,6-tetrahydropyridino-purine, -3H-1,2,3-triazolo[4,5-d)pyrimidine, -purin-8-one, and -7H-pyrrolo[2,3-d]pyrimidine derivatives.
    Kumagai T; Okubo T; Kataoka-Okubo H; Chaki S; Okuyama S; Nakazato A
    Bioorg Med Chem; 2001 May; 9(5):1357-63. PubMed ID: 11377193
    [TBL] [Abstract][Full Text] [Related]  

  • 71. 4-Aryl-2-anilinopyrimidines as corticotropin-releasing hormone (CRH) antagonists.
    Cocuzza AJ; Hobbs FW; Arnold CR; Chidester DR; Yarem JA; Culp S; Fitzgerald L; Gilligan PJ
    Bioorg Med Chem Lett; 1999 Apr; 9(7):1057-62. PubMed ID: 10230640
    [TBL] [Abstract][Full Text] [Related]  

  • 72. An insight into antagonist binding and induced conformational dynamics of class B GPCR corticotropin-releasing factor receptor 1.
    Xu J; Wang Z; Liu P; Li D; Lin J
    Mol Biosyst; 2015 Jul; 11(7):2042-50. PubMed ID: 25980590
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Synthesis and biological activity of fluoro-substituted pyrrolo[2,3-d]pyrimidines: the development of potential positron emission tomography imaging agents for the corticotropin-releasing hormone type 1 receptor.
    Hsin LW; Webster EL; Chrousos GP; Gold PW; Eckelman WC; Contoreggi C; Rice KC
    Bioorg Med Chem Lett; 2000 Apr; 10(8):707-10. PubMed ID: 10782669
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Thiazolo[4,5-d]pyrimidine thiones and -ones as corticotropin-releasing hormone (CRH-R1) receptor antagonists.
    Beck JP; Curry MA; Chorvat RJ; Fitzgerald LW; Gilligan PJ; Zaczek R; Trainor GL
    Bioorg Med Chem Lett; 1999 Apr; 9(8):1185-8. PubMed ID: 10328310
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.
    Denhart DJ; Zuev D; Ditta JL; Hartz RA; Ahuja VT; Mattson RJ; Huang H; Mattson GK; Zueva L; Nielsen JM; Kozlowski ES; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2052-5. PubMed ID: 23465610
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Design, synthesis and evaluation of constrained tetrahydroimidazopyrimidine derivatives as antagonists of corticotropin-releasing factor type 1 receptor (CRF1R).
    Vrudhula VM; Dasgupta B; Pin SS; Burris KD; Balanda LA; Fung LK; Fiedler T; Browman KE; Taber MT; Zhang J; Macor JE; Dubowchik GM
    Bioorg Med Chem Lett; 2010 Mar; 20(6):1905-9. PubMed ID: 20185312
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Design and synthesis of 3-(2-pyridyl)pyrazolo[1,5-a]pyrimidines as potent CRF1 receptor antagonists.
    Huang CQ; Wilcoxen KM; Grigoriadis DE; McCarthy JR; Chen C
    Bioorg Med Chem Lett; 2004 Aug; 14(15):3943-7. PubMed ID: 15225703
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
    Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
    J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies.
    Hodge CN; Aldrich PE; Wasserman ZR; Fernandez CH; Nemeth GA; Arvanitis A; Cheeseman RS; Chorvat RJ; Ciganek E; Christos TE; Gilligan PJ; Krenitsky P; Scholfield E; Strucely P
    J Med Chem; 1999 Mar; 42(5):819-32. PubMed ID: 10072680
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Corticotropin-releasing factor type-1 receptor antagonists: the next class of antidepressants?
    Nielsen DM
    Life Sci; 2006 Jan; 78(9):909-19. PubMed ID: 16122764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.